aTYR PHARMA (ATYR) Total Debt Growth (3y) (2017 - 2020)
Analysis
aTYR PHARMA (ATYR) Total Debt Growth (3y) (2017 - 2020) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | -0.51% |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | -0.71% |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 0.08% |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | - |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | - |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 8.78% |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | - |
| 10 | aTYR PHARMA | 35.31 Mn | -22.30 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2020 | -40.79% |
| Jun 30, 2020 | -30.11% |
| Mar 31, 2020 | -10.49% |
| Dec 31, 2019 | -2.88% |
| Sep 30, 2019 | 58.87% |
| Jun 30, 2019 | 52.68% |
| Mar 31, 2019 | 48.76% |
| Dec 31, 2018 | 46.08% |
| Sep 30, 2018 | 44.13% |
| Jun 30, 2018 | 42.67% |
| Mar 31, 2018 | 28.06% |
| Dec 31, 2017 | 24.29% |